Ann Arbor

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer3 trials
• Dermatomyositis and polymyositis (myositis)1 trial
• Liver and biliary tract cancer1 trial
• Sarcoidosis1 trial

Phase

• Phase 12 trials
• Phase 32 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Completed3 trials
• Recruiting3 trials

Lead sponsor

• Arvinas Estrogen Receptor, Inc.2 trials
• Priovant Therapeutics, Inc.2 trials
• Alnylam Pharmaceuticals1 trial
• Olema Pharmaceuticals, Inc.1 trial

Running trials

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

  Contact: Olema Pharmaceuticals, Inc.

• Recruiting

  A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

  NCT06978725· Phase 2/3· Priovant Therapeutics, Inc.· Source

  Contact: Clinical Trial Administrator

• Recruiting

  A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

  NCT06600321· Phase 1· Alnylam Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Sarcoidosis1 recruiting

Closed trials

• Completed

  A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

  NCT05437263· Phase 3· Priovant Therapeutics, Inc.· Source

• Completed

  ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

  NCT05501769· Phase 1· Arvinas Estrogen Receptor, Inc.· Source

• Completed

  A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

  NCT04072952· Phase 1/2· Arvinas Estrogen Receptor, Inc.· Source